MX428411B - Compuestos para tratar la disautonomía familiar - Google Patents
Compuestos para tratar la disautonomía familiarInfo
- Publication number
- MX428411B MX428411B MX2022007094A MX2022007094A MX428411B MX 428411 B MX428411 B MX 428411B MX 2022007094 A MX2022007094 A MX 2022007094A MX 2022007094 A MX2022007094 A MX 2022007094A MX 428411 B MX428411 B MX 428411B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- familial dysautonomia
- treating familial
- treating
- description relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947049P | 2019-12-12 | 2019-12-12 | |
| PCT/US2020/063612 WO2021118929A1 (en) | 2019-12-12 | 2020-12-07 | Compounds for treating familial dysautonomia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2022007094A MX2022007094A (es) | 2022-07-11 |
| MX428411B true MX428411B (es) | 2025-11-13 |
Family
ID=74046197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007094A MX428411B (es) | 2019-12-12 | 2020-12-07 | Compuestos para tratar la disautonomía familiar |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230057568A1 (enExample) |
| EP (1) | EP4072677A1 (enExample) |
| JP (2) | JP2023506488A (enExample) |
| KR (1) | KR20220113700A (enExample) |
| CN (1) | CN115209955A (enExample) |
| AU (1) | AU2020402717A1 (enExample) |
| BR (1) | BR112022011364A2 (enExample) |
| CA (1) | CA3160053A1 (enExample) |
| CL (1) | CL2022001523A1 (enExample) |
| CO (1) | CO2022008195A2 (enExample) |
| IL (1) | IL293764A (enExample) |
| MX (1) | MX428411B (enExample) |
| PE (1) | PE20221581A1 (enExample) |
| WO (1) | WO2021118929A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020222881C1 (en) | 2019-02-13 | 2026-01-22 | Ptc Therapeutics, Inc. | Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia |
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
| JP2024533264A (ja) * | 2021-09-07 | 2024-09-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 神経原性疾患を処置するための方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK6652000A3 (en) * | 1997-11-11 | 2002-05-09 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| WO2005007083A2 (en) * | 2003-06-18 | 2005-01-27 | Smithkline Beecham Corporation | Chemical compounds |
| JP2009007341A (ja) * | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| EP2014663A1 (de) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| US20130317045A1 (en) * | 2010-09-01 | 2013-11-28 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
| CN103242341B (zh) * | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用 |
| CA3199430A1 (en) * | 2015-01-16 | 2016-07-21 | The General Hospital Corporation | Compounds for improving mrna splicing |
| GB201700814D0 (en) * | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| CN110312528B (zh) * | 2017-02-20 | 2022-02-18 | 国立大学法人京都大学 | 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法 |
| AU2020222881C1 (en) * | 2019-02-13 | 2026-01-22 | Ptc Therapeutics, Inc. | Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia |
| WO2020167624A1 (en) * | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
-
2020
- 2020-12-07 KR KR1020227019352A patent/KR20220113700A/ko not_active Ceased
- 2020-12-07 EP EP20829474.4A patent/EP4072677A1/en active Pending
- 2020-12-07 MX MX2022007094A patent/MX428411B/es unknown
- 2020-12-07 BR BR112022011364A patent/BR112022011364A2/pt not_active Application Discontinuation
- 2020-12-07 AU AU2020402717A patent/AU2020402717A1/en not_active Abandoned
- 2020-12-07 IL IL293764A patent/IL293764A/en unknown
- 2020-12-07 JP JP2022535707A patent/JP2023506488A/ja active Pending
- 2020-12-07 CN CN202080096472.5A patent/CN115209955A/zh active Pending
- 2020-12-07 US US17/783,941 patent/US20230057568A1/en active Pending
- 2020-12-07 CA CA3160053A patent/CA3160053A1/en active Pending
- 2020-12-07 WO PCT/US2020/063612 patent/WO2021118929A1/en not_active Ceased
- 2020-12-07 PE PE2022001057A patent/PE20221581A1/es unknown
-
2022
- 2022-06-09 CL CL2022001523A patent/CL2022001523A1/es unknown
- 2022-06-10 CO CONC2022/0008195A patent/CO2022008195A2/es unknown
-
2025
- 2025-06-11 JP JP2025097641A patent/JP2025133750A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220113700A (ko) | 2022-08-16 |
| CO2022008195A2 (es) | 2022-07-29 |
| CL2022001523A1 (es) | 2023-03-31 |
| BR112022011364A2 (pt) | 2022-08-23 |
| US20230057568A1 (en) | 2023-02-23 |
| EP4072677A1 (en) | 2022-10-19 |
| PE20221581A1 (es) | 2022-10-06 |
| MX2022007094A (es) | 2022-07-11 |
| AU2020402717A1 (en) | 2022-06-23 |
| CN115209955A (zh) | 2022-10-18 |
| WO2021118929A1 (en) | 2021-06-17 |
| JP2023506488A (ja) | 2023-02-16 |
| JP2025133750A (ja) | 2025-09-11 |
| CA3160053A1 (en) | 2021-06-17 |
| IL293764A (en) | 2022-08-01 |